The attenuated Salmonella vaccine approach for the control of Helicobacter pylori-related diseases

Vaccine

Volumn 17, Issue 13-14, 1999, Pages 1667-1673

  Gómez Duarte, Oscar G ^a   Bumann, Dirk ^b   Meyer, Thomas F ^a,b  

^a MAX PLANCK INST FÜR BIOLOGIE   (Germany)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SALMONELLOSIS VACCINE;

ACTIVE IMMUNIZATION; ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; CONFERENCE PAPER; DISEASE ASSOCIATION; GASTRITIS; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; PRIORITY JOURNAL; STOMACH LYMPHOMA; STRAIN DIFFERENCE; TREATMENT FAILURE; VACCINATION;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; DRUG DELIVERY SYSTEMS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICE; SALMONELLA; VACCINES, ATTENUATED;

EID: 0344141395     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00436-8     Document Type: Conference Paper

References (81)

1. Warren J.R. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. i:1983;1273.
2. Marschall B.J. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. i:1983;1273-1275.
3. Marschall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. I:1983;1311-1314.
4. Feldman R.A., Eccersley A.J., Hardie J.M. Epidemiology of Helicobacter pylori: acquisition, transmission, population prevalence and disease-to-infection ratio. Br. Med. Bull. 54:1998;39-53.
5. Goodman K.J., Correa P., Tengana H.J.et al. Helicobacter pylori infection in the colombian Andes: a population-based study of transmission pathways. Am. J. Epidemiol. 144:1996;290-299.
6. Rowland M., Drumm B. Clinical significance of Helicobacter infection in children. Br. Med. Bull. 54:1998;95-103.
7. Owen R.J. Helicobacter-species classification and identification. Br. Med. Bull. 54:1998;17-30.
8. Xiang Z., Censini S., Bayeli P.F.et al. Analysis of expression of CagA and VacA virulence factors in 43 strain of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect. Immun. 63:1995;94-98.
9. Marchetti M., Aricò B., Burroni D., Figura N., Rapuolli R., Ghiara P. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science. 267:1995;1655-1658.
10. Akopyants N.S., Clifton S.W., Kersulyte D.et al. Analyses of the cag pathogenicity island of Helicobacter pylori. Mol. Microbiol. 28:1998;37-53.
11. Covacci A., Flakow S., Berg D.E., Rapuolli R. Did the inheritance of a pathogenicity island modify the virulence of Helicobacter pylori? Trends Microbiol. 5:1997;205-208.
12. Segal E.D., Lange C., Covacci A., Tompkins L.S., Falkow S. Induction of host signal transduction pathways by Helicobacter pylori. Proc. Natl. Acad. Sci. USA. 94:1997;7595-7599.
13. Glocker E., Lange S., Covacci A.et al. Proteins encoded by the cag pathogenicity island of Helicobacter pylori are required for NF-kB activation. Infect. Immun. 66:1998;2346-2348.
14. Kaper J.B., McDaniel T.K., Jarvis K.G., Gómez-Duarte O.G. Genetics of virulence of enteropathogenic E. coli. Adv. Exp. Med. Biol. 412:1997;279-287.
15. Crabtree J.E., Taylor J., Wyatt J.I.et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa proetin, peptic ulceration, and gastric pathology. Lancet. 338:1993;332-335.
16. Parsonet J., Replogle M., Yang S., Hiatt R. Seroprevalence of CagA-positive strains among Helicobacter pylori-infected healthy young adults. J. Infect. Dis. 175:1997;1240-1242.
17. Weel J., van der Hulst R.W., Gerrits Y.et al. The interrelation between cytotoxin associated gene A, vacuolating cytotoxin and Helicobacter pylori related diseases. J. Infect. Dis. 173:1996;1171-1175.
18. Leunk R.D., Johnson P.T., David B.C., Kraft W.G., Morgan D.R. Cytotoxic activity in broth culture filtrates of Campylobacter pylori. J. Med. Microbiol. 26:1988;93-99.
19. Ghiara P., Marchetti M., Blaser J.et al. Role of Helicobacter pylori virulence factors vacuolating cytotoxin, CagA and urease in a mouse model of disease. Infect. Immun. 63:1995;4154-4160.
20. Phadnis S.H., Ilver D., Janzon L., Normark S., Westblom T.U. Pathological significance and molecular characterization of the vacuolating toxin gene of Helicobacter pylori. Infect. Immun. 62:1994;1557-1565.
21. Tummuru M.K., Cover T.L., Blaser M.J. Mutation of the cytotoxin-associated cagA gene does not affect the vacuolating cytotoxin activity of Helicobacter pylori. Infect. Immun. 62:1994;2609-2613.
22. Garner J.A., Cover T.L. Binding and internalization of the Helicobacter pylori vacuolating cytotoxin by epithelial cells. Infect. Immun. 64:1996;4197-4203.
23. Massari P., Manetti R., Burroni D., Nuti S., Norais N., Rapuoli R., Telford J.L. Binding of the Helicobacter pylori vacuolating cytotoxin to target cells. Infect. Immun. 66:1998;3981-3984.
24. Ricci V., Ciacci C., Zarrilli R.et al. Effect of Helicobacter pylori on gastric epithelial cell migration and proliferation in vitro: role of VacA and CagA. Infect. Immun. 64:1996;2829-2833.
25. Pan Z., Terg D.E., van der Hulst R.W.et al. Prevalence of vacuolating cytotoxin production and distribution of distinct vacA alleles in Helicobacter pylori from China. J. Infect. Dis. 178:1997;220-226.
26. Cao P., McClain M.S., Forsyth M.H., Cover T.L. Extracellular release of antigenic proteins by Helicobacter pylori. Infect. Immun. 66:1998;2984-2986.
27. Vanet A., Labigne A. Evidence for specific secretion rather than autolysis in the release of some Helicobacter pylori proteins. Infect. Immun. 66:1998;1023-1027.
28. Mobley H.L., Island M.D., Hausinger R.P. Molecular biology of microbial ureases. Microbial. Rev. 59:1995;451-480.
29. Tsuda M., Karita M., Morshed M.G., Okita K., Nakasaki T.A. A urease-negative mutant of Helicobacter pylori constructed by allelic exchange mutagenesis lacks the ability to colonize the nude mice stomach. Infect. Immun. 62:1994;3586-3589.
30. Eaton K.A., Krakowka S. Effect of gastric pH on urease-dependent colonization of gnotobiotic piglets by Helicobacter pylori. Infect. Immun. 62:1994;3604-3607.
31. Makristathis A., Hirschl A.M., Willinger B., Labigne A., Rikita A. Highly significant role of Helicobacter pylori urease in phagocytosis and production of oxygen metabolites by human granulocytes. J. Infect. Dis. 177:1998;803-806.
32. Dent J.G., McNulty C.A., Uff J.S., Gear M.W., Wilkinson S.P. Campylobacter pylori urease: a new serological test. Lancet. i:1988;1002.
33. Bell G.D. Clinical practice-breath test. Br. Med. Bull. 54:1998;187-193.
34. Glauser M., Michetti P., Blum A.L., Corthésy-Theulaz I. Carbon-14-urea test as a noninvasive method to monitor colonization in mice. Digestion. 57:1996;30-34.
35. Goodman K.J., Correa P. The transmission of Helicobacter pylori. A critical review of the evidence. Int. J. Epidemiol. 24:1995;875-887.
36. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease Helicobacter pylori in peptic ulcer disease. JAMA. 272:1994;65-69.
37. Atherton J.C. H. pylori virulence factors. Br. Med. Bull. 54:1998;105-120.
38. Labigne A., Reuse H. Determinants of Helicobacter pylori pathogenicity. Infect. Age. Dis. 5:1996;191-202.
39. Parsonet J., Hanssen S., Rodriguez L.et al. Helicobacter pylori infection and gastric lymphoma. N. Engl. J. Med. 330:1994;1267-1271.
40. Hussel T., Isascson P.G., Crabtree J.E., Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet. 342:1993;571-574.
41. Wotherspoon A.C., Doglioni C., Cooper M., Robinson J. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 342:1993;575-577.
42. Correa P., Haenszel W., Cuello C., Tannenboum S., Archer M.A. A model for gastric cancer epidemiology. Lancet. 2:1975;58-60.
43. Hansson L., Nyrén O., Hsing W.et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N. Engl. J. Med. 35:1996;242-249.
44. Kuipers E.J., Lundell L., Klinkerberg-Knol E.et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazol or funduplication. N. Engl. J. Med. 334:1996;1018-1022.
45. Walsh J.H., Peterson W. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N. Engl. J. Med. 333:1995;984-991.
46. Sung J.J., Chumg S.C., Thomas M.D.et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N. Engl. J. Med. 332:1995;139-142.
47. Lerang F., Moum B., Haug J.B.et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazol resistance have any clinical relevance? Am. J. Gastroenterol. 92:1997;248-253.
48. Mégraud F. Antibiotic resistance in Helicobacter pylori infection. Br. Med. Bull. 54:1998;207-216.
49. Jorgensen M., Daskalopoulos G., Warburton V., Mitchell H.M., Hazell S.L. Multiple strain colonization and metronidazol resistance in Helicobacter pylori-infected patients: identification from sequential and multiple biopsy specimens. J. Infect. Dis. 174:1995;631-635.
50. Midolo P.D., Lambert J.R., Turnidge J. Metronidazol resistance: a predictor of failure of Helicobacter pylori eradication by triple therapy. J. Gastroenterol. Hepatol. 11:1996;290-292.
51. Raymond J., Kalach N., Bergeret Met al. Effect of metronidazol resistance on bacterial eradication of Helicobacter pylori in infected children. Antimicrob. Chemother. 42:1998;1334-1335.
52. Wang G., Taylor D.E. Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance of macrolide-lincosamide-streptogramin B antibiotics. Antimicrob. Chemother. 42:1998;1852-1958.
53. Krakowka S., Eaton K.A., Rings D.M. Occurrence of gastric ulcers in Gnotobiotic piglets colonized by Helicobacter pylori. Infect. Immun. 63:1995;2352-2355.
54. Lee A. Animal models for host-pathogen interaction studies. Br. Med. Bull. 54:1998;163-173.
55. Shuto R., Fujioka T., Kubota T., Nasu M. Experimental gastritis induced by Helicobacter pylori in Japanese monkeys. Infect. Immun. 61:1993;933-999.
56. Chen M., Lee A., Hazell S. Immunisation against gastric Helicobacter infection in a mouse/Helicobacter felis model. Lancet. 339:1992;1120-1121.
57. Lee A., Chen M. Successful immunization against gastric infection with Helicobacter species: use of cholera toxin B-subunit-whole cell vaccine. Infect. Immun. 62:1994;3594-3597.
58. Ferrero R.L., Thiberge J., Huerre M., Labigne A. Recombinant antigens prepared from the urease subunits of Helicobacter spp.: evidence of protection in a mouse model of gastric infection. Infect. Immun. 62:1994;4981-4989.
59. Pappo J., Thomas W.D. Jr., Kabok Z., Taylor N.S., Murphy J.C., Fox J.G. Effect of oral immunization with recombinant urease on murine Helicobacter felis gastritis. Infect. Immun. 63:1995;1246-1252.
60. Kleanthous H., Myers G.A., Georgakopoulos K.M.et al. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect. Immun. 66:1998;2879-2886.
61. Blanchard T.G., Czinn S.J., Maurer R., Thomas W.D., Soman G., Nedrud J.G. Urease-specific monoclonal antibodies prevent Helicobacter felis infection in mice. Infect. Immun. 63:1995;1394-1399.
62. Michetti P., Corthésy-Theulaz I., Davin C., Haas R., Vaney A.C., Heitz M., Bille J., Kraehenbuhl J.P., Saraga E., Blum A.L. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology. 107:1994;1002-1011.
63. Ghiara P., Rossi M., Marchetti M.et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect. Immun. 65:1997;4996-5002.
64. Marchetti M., Rossi M., Giannelli V.et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine. 16:1998;33-37.
65. Ferrero R. L, Thiberge J.M., Kansau I., Wuscher N., Huerre M., Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc. Natl. Acad. Sci. USA. 92:1995;6499-6503.
66. Radcliff F.J., Hazell S.L., Kolesnikow T., Doidge C., Lee A. Catalase, a novel antigen for Helicobacter pylori vaccination. Infect. Immun. 65:1997;4668-4674.
67. Hopkins S., Kraehenbuhl J., Schodel F.et al. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect. Immun. 63:1995;3270-3286.
68. Galen J., Gómez-Duarte O.G., Losonsky G., Halpern J., Lauderbaugh C., Kaintuk S., Reyman M., Levine M.M. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine. 15:1997;700-708.
69. Comoy E.E., Capron A., Thyphronitis G. In vivo induction of type 1 and 2 immune responses against protein antigens. Int. Immunol. 9:1997;523-531.
70. Harokopakis E., Hajishengallis G., Greenway T.E., Russel M.W., Michalec S.M. Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of coexpressed cholera toxin A2 and B subunits. Infect. Immun. 65:1997;1445-1454.
71. Vancott J.L., Staats H.F., Pascual D.W.et al. Regulation of mucosal and systemic antibody responses by T helper subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. J. Immunol. 156:1997;1504-1514.
72. Chatfield S.N., Strugnell R.A., Dougan G. Live Salmonella as vaccine carries of foreign antigenic determinants. Vaccine. 7:1989;495-498.
73. Tacket C.O., Hone D.M., Curtiss R. IIIet al. Comparison of the safety and immunogenicity of DaroC DaroD and Dcya Dcrp Salmonella typhi strains in adult volunteers. Infect. Immun. 60:1992;536-541.
74. Tacket C.O., Hone D.M., Losonsky G.A., Guers L., Edelman R., Levine M.M. Clinical acceptability and immunogenicity of CVD908 Salmonella typhi vaccine strain. Vaccine. 10:1992;443-446.
75. Tacket C.O., Sztein M.B., Losonsky G.A., Wasserman S.S.et al. Safety of live oral Salmonella typhi vaccine strains with deletions in hrtA, and aroC aroD and immune response in humans. Infect. Immun. 65:1997;452-456.
76. Hoiseth S.K., Stocker B.A. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 291:1981;238-239.
77. Hone D.M., Harris A.M., Chatfield S., Dougan G., Levine M.M. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine. 9:1991;810-816.
78. Miller S.I., Kukral A.M., Mekalanos J.J. A two-component regulatory system (phoP phoQ) control Salmonella typhimurium virulence. Proc. Natl. Acad. Sci. USA. 86:1989;5054-5058.
79. Curtiss R. III, Kelly S.M. Salmonella typhimurium deletion mutant lacking adenylated cyclase and cyclin AMP receptor protein are avirulent and immunogenic. Infect. Immun. 55:1987;3035-3043.
80. Gómez-Duarte O.G., Lucas B., Yan Z., Panthel K., Haas R., Meyer T.F. Urease subunits A and B delivered by attenuated Salmonella typhimurium vaccine strain protects mice against gastric colonization by Helicobacter pylori. Vaccine. 16:1998;460-471.
81. c expressing urease A and B subunits. Infect. Immun. 66:1998;581-586.